PL206091B1 - Zastosowania daptomycyny - Google Patents
Zastosowania daptomycynyInfo
- Publication number
- PL206091B1 PL206091B1 PL384274A PL38427499A PL206091B1 PL 206091 B1 PL206091 B1 PL 206091B1 PL 384274 A PL384274 A PL 384274A PL 38427499 A PL38427499 A PL 38427499A PL 206091 B1 PL206091 B1 PL 206091B1
- Authority
- PL
- Poland
- Prior art keywords
- daptomycin
- dose
- hours
- use according
- days
- Prior art date
Links
- 108010013198 Daptomycin Proteins 0.000 title claims abstract description 135
- 229960005484 daptomycin Drugs 0.000 title claims abstract description 135
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 title claims abstract description 135
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 25
- 238000011282 treatment Methods 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 29
- 230000037396 body weight Effects 0.000 claims description 18
- 208000035143 Bacterial infection Diseases 0.000 claims description 10
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 10
- 238000001990 intravenous administration Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 abstract description 41
- 231100000483 muscle toxicity Toxicity 0.000 abstract description 29
- 239000003242 anti bacterial agent Substances 0.000 abstract description 16
- 229940088710 antibiotic agent Drugs 0.000 abstract description 16
- 230000003115 biocidal effect Effects 0.000 abstract description 10
- 108010028921 Lipopeptides Proteins 0.000 abstract description 7
- PPKJUHVNTMYXOD-PZGPJMECSA-N c49ws9n75l Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O PPKJUHVNTMYXOD-PZGPJMECSA-N 0.000 abstract description 6
- 229940052337 quinupristin/dalfopristin Drugs 0.000 abstract description 6
- 102000004420 Creatine Kinase Human genes 0.000 description 44
- 108010042126 Creatine kinase Proteins 0.000 description 44
- 241000282472 Canis lupus familiaris Species 0.000 description 22
- 231100000419 toxicity Toxicity 0.000 description 20
- 230000001988 toxicity Effects 0.000 description 20
- 230000000694 effects Effects 0.000 description 16
- 230000036470 plasma concentration Effects 0.000 description 16
- 229940079593 drug Drugs 0.000 description 14
- 208000021642 Muscular disease Diseases 0.000 description 13
- 201000009623 Myopathy Diseases 0.000 description 13
- 230000007850 degeneration Effects 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 11
- 210000003205 muscle Anatomy 0.000 description 11
- 229940126575 aminoglycoside Drugs 0.000 description 10
- 210000001087 myotubule Anatomy 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 241000192125 Firmicutes Species 0.000 description 8
- 208000000112 Myalgia Diseases 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 108010059993 Vancomycin Proteins 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 229960003165 vancomycin Drugs 0.000 description 7
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 7
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 208000010428 Muscle Weakness Diseases 0.000 description 6
- 206010028372 Muscular weakness Diseases 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 208000013465 muscle pain Diseases 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 108010015899 Glycopeptides Proteins 0.000 description 5
- 102000002068 Glycopeptides Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 4
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 208000027136 gram-positive bacterial infections Diseases 0.000 description 4
- 229960003085 meticillin Drugs 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000031729 Bacteremia Diseases 0.000 description 3
- 241000194033 Enterococcus Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000029549 Muscle injury Diseases 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 231100000706 no observed effect level Toxicity 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 108010065152 Coagulase Proteins 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 206010062255 Soft tissue infection Diseases 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 108010034396 Streptogramins Proteins 0.000 description 2
- 108010053950 Teicoplanin Proteins 0.000 description 2
- 229960004909 aminosalicylic acid Drugs 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 2
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000005786 degenerative changes Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- 229940047650 haemophilus influenzae Drugs 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960001608 teicoplanin Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 1
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 1
- 206010058040 Abdominal sepsis Diseases 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 241001464890 Anaerococcus prevotii Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241001464894 Blautia producta Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010005940 Bone and joint infections Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 108010065839 Capreomycin Proteins 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241001517041 Corynebacterium jeikeium Species 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- 241001468179 Enterococcus avium Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241000186588 Erysipelatoclostridium ramosum Species 0.000 description 1
- 241000192016 Finegoldia magna Species 0.000 description 1
- 206010061977 Genital infection female Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 241000194035 Lactococcus lactis Species 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 206010053636 Obstetric infection Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 241001464887 Parvimonas micra Species 0.000 description 1
- 241000192001 Pediococcus Species 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 241000191992 Peptostreptococcus Species 0.000 description 1
- 241000192035 Peptostreptococcus anaerobius Species 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- VRDIULHPQTYCLN-UHFFFAOYSA-N Prothionamide Chemical compound CCCC1=CC(C(N)=S)=CC=N1 VRDIULHPQTYCLN-UHFFFAOYSA-N 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000194049 Streptococcus equinus Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000958215 Streptomyces filamentosus Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108010015940 Viomycin Proteins 0.000 description 1
- OZKXLOZHHUHGNV-UHFFFAOYSA-N Viomycin Natural products NCCCC(N)CC(=O)NC1CNC(=O)C(=CNC(=O)N)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC1=O)C2CC(O)NC(=N)N2 OZKXLOZHHUHGNV-UHFFFAOYSA-N 0.000 description 1
- 241000193462 [Clostridium] innocuum Species 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229960004602 capreomycin Drugs 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- 229960002001 ethionamide Drugs 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960000308 fosfomycin Drugs 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- 229940083579 fusidate sodium Drugs 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229960004905 gramicidin Drugs 0.000 description 1
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960003128 mupirocin Drugs 0.000 description 1
- 229930187697 mupirocin Natural products 0.000 description 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
- 230000009756 muscle regeneration Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 229940074571 peptostreptococcus anaerobius Drugs 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 229940041153 polymyxins Drugs 0.000 description 1
- 230000001374 post-anti-biotic effect Effects 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 229960000918 protionamide Drugs 0.000 description 1
- 229960005206 pyrazinamide Drugs 0.000 description 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 description 1
- 229940081192 rifamycins Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 238000011450 sequencing therapy Methods 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- HJHVQCXHVMGZNC-JCJNLNMISA-M sodium;(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoate Chemical compound [Na+].O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C HJHVQCXHVMGZNC-JCJNLNMISA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003053 thiamphenicol Drugs 0.000 description 1
- OTVAEFIXJLOWRX-NXEZZACHSA-N thiamphenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl)C=C1 OTVAEFIXJLOWRX-NXEZZACHSA-N 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- GXFAIFRPOKBQRV-GHXCTMGLSA-N viomycin Chemical compound N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)C[C@@H](N)CCCN)CNC(=O)[C@@H]1[C@@H]1NC(=N)N[C@@H](O)C1 GXFAIFRPOKBQRV-GHXCTMGLSA-N 0.000 description 1
- 229950001272 viomycin Drugs 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10182898P | 1998-09-25 | 1998-09-25 | |
| US12575099P | 1999-03-24 | 1999-03-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL206091B1 true PL206091B1 (pl) | 2010-06-30 |
Family
ID=26798675
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL384274A PL206091B1 (pl) | 1998-09-25 | 1999-09-24 | Zastosowania daptomycyny |
| PL348328A PL203689B1 (pl) | 1998-09-25 | 1999-09-24 | Zastosowanie daptomycyny |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL348328A PL203689B1 (pl) | 1998-09-25 | 1999-09-24 | Zastosowanie daptomycyny |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US6468967B1 (enExample) |
| EP (2) | EP1115417B1 (enExample) |
| JP (4) | JP4184607B2 (enExample) |
| KR (2) | KR20010075327A (enExample) |
| CN (2) | CN1530136A (enExample) |
| AT (1) | ATE322280T1 (enExample) |
| AU (1) | AU764348B2 (enExample) |
| BR (1) | BR9914051A (enExample) |
| CA (1) | CA2344318C (enExample) |
| CY (3) | CY1105556T1 (enExample) |
| DE (3) | DE122006000049I1 (enExample) |
| DK (2) | DK1674107T3 (enExample) |
| ES (2) | ES2259845T3 (enExample) |
| HK (1) | HK1040363B (enExample) |
| HU (1) | HU230656B1 (enExample) |
| IS (2) | IS5890A (enExample) |
| LU (1) | LU91254I2 (enExample) |
| NL (1) | NL300232I2 (enExample) |
| NO (1) | NO20011454L (enExample) |
| NZ (1) | NZ510690A (enExample) |
| PL (2) | PL206091B1 (enExample) |
| PT (2) | PT1674107T (enExample) |
| RU (1) | RU2363489C9 (enExample) |
| SI (2) | SI1115417T1 (enExample) |
| TR (1) | TR200100841T2 (enExample) |
| WO (1) | WO2000018419A2 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1115417T1 (sl) | 1998-09-25 | 2006-08-31 | Cubist Pharm Inc | Uporaba daptomicina |
| WO2001044272A2 (en) | 1999-12-15 | 2001-06-21 | Cubist Pharmaceuticals, Inc. | Daptomycin analogs as antibacterial agents |
| US6696412B1 (en) | 2000-01-20 | 2004-02-24 | Cubist Pharmaceuticals, Inc. | High purity lipopeptides, Lipopeptide micelles and processes for preparing same |
| EP1343811A4 (en) * | 2000-12-18 | 2004-12-08 | Cubist Pharm Inc | METHOD FOR PRODUCING PURIFIED LIPOPEPTIDES |
| WO2002059145A1 (en) * | 2000-12-18 | 2002-08-01 | Cubist Pharmaceuticals, Inc. | Methods for preparing purified lipopeptides |
| US20060014674A1 (en) | 2000-12-18 | 2006-01-19 | Dennis Keith | Methods for preparing purified lipopeptides |
| EP1932853A1 (en) | 2001-08-06 | 2008-06-18 | Cubist Pharmaceutical Inc. | Novel depsipeptides and process for preparing same |
| AU2003274927A1 (en) * | 2002-08-23 | 2004-03-11 | Genome Therapeutics Corporation | Methods and reagents for preventing bacteremias |
| US20060074014A1 (en) * | 2002-11-18 | 2006-04-06 | Vicuron Pharmaceuticals Inc. | Dalbavancin compositions for treatment of bacterial infections |
| US20050277581A1 (en) * | 2002-11-18 | 2005-12-15 | Vicuron Pharmaceuticals Inc. | Dalbavancin compositions for treatment of bacterial infections |
| US20050220862A1 (en) | 2004-03-31 | 2005-10-06 | Bernstein Joel E | Compositions with reduced hepatotoxicity |
| US20060004185A1 (en) * | 2004-07-01 | 2006-01-05 | Leese Richard A | Peptide antibiotics and peptide intermediates for their prepartion |
| US20060014677A1 (en) * | 2004-07-19 | 2006-01-19 | Isotechnika International Inc. | Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds |
| US20080051326A1 (en) * | 2004-11-12 | 2008-02-28 | Alexander Dylan C | Antiinfective Lipopeptides |
| US8546423B2 (en) | 2005-05-18 | 2013-10-01 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
| US7838532B2 (en) * | 2005-05-18 | 2010-11-23 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
| US20070238630A1 (en) * | 2006-03-29 | 2007-10-11 | Phillips Douglas H | Subcutaneous skin cleanser |
| EP2018864A1 (en) * | 2007-07-23 | 2009-01-28 | Biomet Deutschland GmbH | Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
| WO2009111422A2 (en) * | 2008-03-04 | 2009-09-11 | Elan Pharmaceuticals, Inc. | Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens |
| WO2010030317A2 (en) | 2008-07-17 | 2010-03-18 | Acorda Therapeutics, Inc. | Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure |
| DE102008046610A1 (de) * | 2008-09-09 | 2010-03-11 | Biomet Deutschland Gmbh | Verwendung einer pharmazeutischen Zusammensetzung zur lokalen Infektionstherapie sowie Medizinprodukt |
| US8629139B2 (en) | 2008-10-07 | 2014-01-14 | Mpex Pharmaceuticals, Inc. | Topical use of Levofloxacin for reducing lung inflammation |
| HUE038428T2 (hu) | 2008-10-07 | 2018-10-29 | Horizon Orphan Llc | Aeroszol fluorokinolon készítmények javított farmakokinetika érdekében |
| US8809263B2 (en) * | 2008-10-24 | 2014-08-19 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Anti-infective hydroxy-phenyl-benzoates and methods of use |
| EP2379580B1 (en) * | 2008-12-22 | 2013-10-23 | Cubist Pharmaceuticals, Inc. | Novel antibacterial agents for the treatment of gram positive infections |
| US8343912B2 (en) | 2008-12-23 | 2013-01-01 | Biosource Pharm, Inc. | Antibiotic compositions for the treatment of gram negative infections |
| US8450300B2 (en) * | 2009-07-13 | 2013-05-28 | Cempra Pharmaceuticals Inc. | Fusidic acid dosing regimens for treatment of bacterial infections |
| CA2767614C (en) * | 2009-07-13 | 2019-01-15 | Cempra Pharmaceuticals Inc. | Fusidic acid dosing regimens for treatment of bacterial infections |
| ES2739979T3 (es) | 2009-09-04 | 2020-02-05 | Horizon Orphan Llc | Uso de levofloxacino en aerosol para el tratamiento de la fibrosis quística |
| CN108785654A (zh) | 2009-11-23 | 2018-11-13 | 丘比斯特制药有限责任公司 | 脂肽组合物和相关方法 |
| US8247394B2 (en) | 2010-06-02 | 2012-08-21 | Cempra Pharmaceuticals Inc. | Methods of treating urethritis and related infections using fusidic acid |
| US8415307B1 (en) | 2010-06-23 | 2013-04-09 | Biosource Pharm, Inc. | Antibiotic compositions for the treatment of gram negative infections |
| WO2013059610A1 (en) * | 2011-10-20 | 2013-04-25 | Trius Therapeutics, Inc. | Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use |
| US8933233B2 (en) | 2012-03-30 | 2015-01-13 | Cubist Pharmaceuticals, Inc. | 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors |
| HUE071031T2 (hu) * | 2012-09-11 | 2025-07-28 | Hospira Australia Pty Ltd | Daptomicinkészítmények és alkalmazásaik |
| CN103006562B (zh) * | 2013-01-21 | 2014-09-17 | 西南大学 | 达托霉素醇质体制剂 |
| CA2904387C (en) | 2013-03-15 | 2021-12-07 | Melinta Therapeutics, Inc. | Methods of treating infections in overweight and obese patients using antibiotics |
| US10647746B2 (en) | 2016-04-08 | 2020-05-12 | Versitech Limited | Antibacterial cyclic lipopeptides |
| US11667674B2 (en) | 2016-04-08 | 2023-06-06 | Versitech Limited | Antibacterial cyclic lipopeptides |
| CN109310735A (zh) * | 2016-05-13 | 2019-02-05 | 我希望增效剂公司 | 新阳离子肽spr741对抗生素活性的增效作用 |
| CN114788814B (zh) * | 2021-01-26 | 2023-10-13 | 浙江创新生物有限公司 | 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE32333E (en) | 1978-10-16 | 1987-01-20 | Eli Lilly And Company | A-21978 Antibiotics and process for their production |
| USRE32455E (en) | 1978-10-16 | 1987-07-07 | Eli Lilly And Company | A-21978 antibiotics and process for their production |
| USRE32310E (en) | 1982-05-21 | 1986-12-16 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| US4524135A (en) | 1982-05-21 | 1985-06-18 | Eli Lilly And Company | A-21978C cyclic peptides |
| US4482487A (en) | 1982-05-21 | 1984-11-13 | Eli Lilly And Company | A-21978C cyclic peptides |
| US4537717A (en) | 1982-05-21 | 1985-08-27 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| USRE32311E (en) | 1982-05-21 | 1986-12-16 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| US4885243A (en) | 1984-10-09 | 1989-12-05 | Eli Lilly And Company | Process for producing A-21978C derivatives |
| US4800157A (en) | 1985-09-09 | 1989-01-24 | Eli Lilly And Company | Process for producing the A-21978C antibiotics |
| US4874843A (en) | 1987-12-03 | 1989-10-17 | Eli Lilly And Company | Chromatographic purification process |
| ZA883887B (en) | 1987-06-10 | 1990-02-28 | Lilly Co Eli | Chromatographic purification process |
| EP0386951A3 (en) | 1989-03-06 | 1992-05-20 | Eli Lilly And Company | An improved diluent formulation for daptomycin |
| FR2755857B1 (fr) | 1996-11-19 | 1998-12-24 | Rhone Poulenc Rorer Sa | Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation |
| FR2772272B1 (fr) * | 1997-12-16 | 2000-01-14 | Rhone Poulenc Rorer Sa | Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation |
| SI1115417T1 (sl) | 1998-09-25 | 2006-08-31 | Cubist Pharm Inc | Uporaba daptomicina |
| US9393093B2 (en) | 2008-02-18 | 2016-07-19 | Covidien Lp | Clip for implant deployment device |
-
1999
- 1999-09-24 SI SI9930904T patent/SI1115417T1/sl unknown
- 1999-09-24 ES ES99949913T patent/ES2259845T3/es not_active Expired - Lifetime
- 1999-09-24 NZ NZ510690A patent/NZ510690A/xx not_active IP Right Cessation
- 1999-09-24 PL PL384274A patent/PL206091B1/pl unknown
- 1999-09-24 EP EP99949913A patent/EP1115417B1/en not_active Revoked
- 1999-09-24 WO PCT/US1999/022366 patent/WO2000018419A2/en not_active Ceased
- 1999-09-24 PT PT60066974T patent/PT1674107T/pt unknown
- 1999-09-24 KR KR1020017003735A patent/KR20010075327A/ko not_active Ceased
- 1999-09-24 SI SI9931082A patent/SI1674107T1/sl unknown
- 1999-09-24 HU HU0103874A patent/HU230656B1/hu unknown
- 1999-09-24 DK DK06006697.4T patent/DK1674107T3/en active
- 1999-09-24 US US09/406,568 patent/US6468967B1/en not_active Expired - Lifetime
- 1999-09-24 AU AU62687/99A patent/AU764348B2/en not_active Expired
- 1999-09-24 CA CA002344318A patent/CA2344318C/en not_active Expired - Lifetime
- 1999-09-24 CN CNA200410031708XA patent/CN1530136A/zh active Pending
- 1999-09-24 DK DK99949913T patent/DK1115417T3/da active
- 1999-09-24 ES ES06006697.4T patent/ES2603086T3/es not_active Expired - Lifetime
- 1999-09-24 PT PT99949913T patent/PT1115417E/pt unknown
- 1999-09-24 HK HK02100152.2A patent/HK1040363B/en not_active IP Right Cessation
- 1999-09-24 EP EP06006697.4A patent/EP1674107B8/en not_active Expired - Lifetime
- 1999-09-24 AT AT99949913T patent/ATE322280T1/de active
- 1999-09-24 BR BR9914051-9A patent/BR9914051A/pt not_active Application Discontinuation
- 1999-09-24 PL PL348328A patent/PL203689B1/pl unknown
- 1999-09-24 KR KR1020107006807A patent/KR20100051735A/ko not_active Ceased
- 1999-09-24 TR TR2001/00841T patent/TR200100841T2/xx unknown
- 1999-09-24 CN CNB998124982A patent/CN1150029C/zh not_active Ceased
- 1999-09-24 DE DE1999630758 patent/DE122006000049I1/de active Pending
- 1999-09-24 DE DE200612000049 patent/DE122006000049I2/de active Active
- 1999-09-24 JP JP2000571937A patent/JP4184607B2/ja not_active Expired - Lifetime
- 1999-09-24 DE DE69930758T patent/DE69930758T2/de not_active Expired - Lifetime
-
2001
- 2001-03-14 IS IS5890A patent/IS5890A/is unknown
- 2001-03-22 NO NO20011454A patent/NO20011454L/no not_active Application Discontinuation
-
2002
- 2002-02-20 US US10/082,544 patent/US6852689B2/en not_active Expired - Lifetime
-
2003
- 2003-05-27 JP JP2003149968A patent/JP2003321389A/ja not_active Withdrawn
-
2004
- 2004-03-04 RU RU2004106569/14A patent/RU2363489C9/ru active
- 2004-08-17 JP JP2004237765A patent/JP2004339238A/ja not_active Withdrawn
-
2006
- 2006-04-18 CY CY20061100536T patent/CY1105556T1/el unknown
- 2006-06-23 NL NL300232C patent/NL300232I2/nl unknown
- 2006-06-28 LU LU91254C patent/LU91254I2/fr unknown
- 2006-07-18 CY CY200600003C patent/CY2006003I1/el unknown
- 2006-09-22 JP JP2006258107A patent/JP2006335773A/ja not_active Withdrawn
-
2009
- 2009-03-10 IS IS8807A patent/IS8807A/is unknown
-
2016
- 2016-11-24 CY CY20161101219T patent/CY1118334T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL206091B1 (pl) | Zastosowania daptomycyny | |
| KR100900208B1 (ko) | 감염의 치료에 대해 토탈 솔루션을 제공하는 항생제 배합물 | |
| Leonard et al. | Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram‐positive infections | |
| Bryskier | Anti-anaerobic activity of antibacterial agents | |
| Ross et al. | Glycopeptide pharmacodynamics | |
| ZA200102389B (en) | Methods for administration of antibiotics. | |
| HK1094672A (en) | Use of daptomycin | |
| CZ20011014A3 (cs) | Farmaceutické přípravky obsahující lipoproteinová antibiotika | |
| Sun et al. | Daptomycin | |
| Hermsen et al. | Glycopeptide pharmacodynamics | |
| De Gaudio | Therapeutic Options for the Treatment of Gram-Positive Infections | |
| Ziglam et al. | New therapeutic agents for resistant Gram-positive infections | |
| Shankar et al. | Newer antibiotics | |
| DE GAUDIO | Therapeutic Options for the Treatment | |
| Reed | Antibiotics for MRSA infections | |
| Reed | Antibiotics for 10 MRSA Infections |